Emil Kuriakose

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Sébastien Jeay, Stéphane Ferretti, Philipp Holzer et al. · Cancer Research · 2018 · 85 citations · Full text

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

Sundar Jagannath, Anuja Roy, Jonathan Kish et al. · Expert Review of Hematology · 2016 · 41 citations

Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours

Aung Naing, Todd M. Bauer, K. Papadopoulos et al. · Annals of Oncology · 2019 · 41 citations · Full text

Oncology, Genitourinary Cancer, Medicine +8

Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera

Emil Kuriakose, Katherine Vandris, Y. Lynn Wang et al. · Haematologica · 2011 · 35 citations · Full text

First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours

Aung Naing, Kyriakos P. Papadopoulos, Michael J. Pishvaian et al. · BMJ Oncology · 2024 · 27 citations · Full text